Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ut are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540 and PS178990, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- According to a new market research ... by Deployment Mode (Web based, On-Premise, Cloud-Based), by End ... by Component - Global Trends & Forecast to 2019", ... $501.1 Million 2014, and is projected to reach $722.7 ... 2014 to 2019. Browse 60 T ...
(Date:8/27/2015)... The nation,s newest Actos trial gets underway Thursday, August 27 ... courtroom.  Attorneys representing two southern Nevada ... after using the diabetes drug Actos. "Takeda Pharmaceuticals ... that their drug Actos caused an increased risk of bladder ... hold Takeda responsible it is appropriate to seek substantial punitive ...
(Date:8/27/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), the maker ... abstracts featuring the use of ActiPatch®, its novel musculoskeletal ... Congress of the European Pain Federation EFIC®, ... 2015. The Company will also be exhibiting at the ... Bagnato , department clinical and experimental rheumatology from the ...
Breaking Medicine Technology:Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 42 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... YORK, Oct. 18, 2011 Reportlinker.com announces ... available in its catalogue: ... to 2020 http://www.reportlinker.com/p0657234/Cervarix-Cervical-Cancer---Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Analysis and Forecasts to 2020 ...
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
Cached Medicine Technology:Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 2Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 3Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 4Orthopedic Biomaterials, The World Market 2Orthopedic Biomaterials, The World Market 3Orthopedic Biomaterials, The World Market 4
(Date:8/27/2015)... ... August 27, 2015 , ... Healthpointe is proud to welcome ... Clinic in Los Angeles. Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe ... and diseases. Dr. Priebe also practices in Healthpointe’s La Mirada clinic and Garden Grove ...
(Date:8/27/2015)... JOHNSON CITY, Tenn. (PRWEB) , ... August 27, 2015 , ... ... Technology LLC, DBA All Clear System. The agreement will enable both Johnson City, Tenn.-based ... , All Clear System is a cloud-based safety product that caters to organizations in ...
(Date:8/27/2015)... ... 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, ... new facility will be located at US Highway 19 North and Highlands Boulevard, less than ... and work on the project is slated to begin in September 2015. , ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch on ... having twelve offices in three counties, LA, Orange and San Bernardino. Their ... Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and Innovation ...
(Date:8/27/2015)... PITTSBURGH, PA (PRWEB) , ... August 27, 2015 , ... ... of the shower and tub," said an inventor from Camp Hill, Pa. "I developed ... He created a prototype for the BATH AND SHOWER GRIP to provide a helping ...
Breaking Medicine News(10 mins):Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
... You,re visiting the dentist for what you think is a ... need a root canal. Though it,s a term you,ve probably ... you may have several questions and feel apprehensive about your ... quite some time. The Pennsylvania Dental Association (PDA) wants to ...
... Healthcare is an industry faced with unprecedented uncertainty. ... overcome the noise and clearly communicate relevant and timely ... company Griffin York & Krause (GY&K) reaffirmed its commitment ... been honored with six national CardioVascular Advertising (CVA) Awards. ...
... New GREENGUARD product certification pilot significantly expands ... exposure to harmful chemicals from products used in ... The GREENGUARD Environmental Institute (GEI) announces the launch ... program incorporating existing stringent indoor air quality criteria, ...
... -- Mesa Laboratories, Inc. (Nasdaq: MLAB ) today ... quarterly dividend of $.11 per share of common stock, up ... be payable December 15, 2009, to shareholders of record on ... Labs has maintained strong cash positions and has continued to ...
... 12 Christiana Care Health System,s Helen ... in the nation to submit specimens to the Biospecimen ... Project. The project is part of a sweeping initiative ... diagnose, treat and even prevent cancer in the future. ...
... muscular dystrophy, experts say , THURSDAY, Nov. 12 (HealthDay ... into the leg muscles of monkeys helped the animals ... , The Muscular Dystrophy Association, which funded the research, ... to better treatment for people who suffer from muscle ...
Cached Medicine News:Health News:Painful Root Canals Are a Thing of the Past 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 2Health News:Healthcare Organizations Face Tough Marketing Challenges - GY&K Asks 'Are You Relevant?' 3Health News:GREENGUARD Launches Comprehensive Health-Based Certification Pilot Program 2Health News:Christiana Care First Community Hospital to Submit Samples to Cancer Genome Atlas Project 2
... The Infinity Uric Acid single liquid ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Uric Acid reagent provides ...
... The Infinity Glucose Oxidase single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Glucose Oxidase reagent ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... provides a long shelf life that ...
... the profitability of your practice by seeing more ... VELO system you can turn a 14-18 patients ... day practice. By streamlining automated test sequences, youll ... technology is simple to learn; making it easy ...
Medicine Products: